Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Preventing Toxic Effects Of Protein Aggregation In Parkinson’s Disease

This article was originally published in Start Up

Executive Summary

Researchers have shown that a new class of small molecule can inhibit assembly of the protein alpha-synuclein into toxic clumps, a hallmark of Parkinson’s disease. Their work supports other ongoing investigations suggesting that the compound may be useful as a neuroprotective agent for treating a range of diseases characterized by the clumping of amyloid proteins, including Alzheimer’s disease, various types of amyloidosis, and prion disease.

You may also be interested in...



Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s

It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.

Observational Studies Reveal Commonalities Across Neurodegenerative Disorders Like Parkinson’s And Alzheimer’s

It’s all about biomarkers, biomarkers, biomarkers as huge cohort studies amass data in the hunt for clues that can aid in drug development, and the rising tide may lift more than one boat as commonalities among diseases like Alzheimer’s and Parkinson’s are discovered.

Clues From Gaucher's Disease Firm Up New Treatment Strategy For Neurodegeneration

Research linking the cause of the rare genetic disorder Gaucher's disease to mechanisms at work in Parkinsonism and other neurodegenerative conditions could become the underpinning for a broad strategy to treat neurodegeneration. It's part of a growing trend looking at molecular activities in the lysosome, a cellular compartment, for drug targets.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC092290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel